EP3398602A1 — Benzoquinoline inhibitors of vesicular monoamine transporter 2
Assigned to Auspex Pharmaceuticals Inc · Expires 2018-11-07 · 8y expired
What this patent protects
The present invention relates to benzoquinoline inhibitors of vesicular monoamine transporter 2 (VMAT2) of formula I, for use in the treatment of Parkinson's disease levodopa-induced dyskinesia, wherein R1-R27 are hydrogen or deuterium; and at least one of R1-R27 is deuterium.
USPTO Abstract
The present invention relates to benzoquinoline inhibitors of vesicular monoamine transporter 2 (VMAT2) of formula I, for use in the treatment of Parkinson's disease levodopa-induced dyskinesia, wherein R1-R27 are hydrogen or deuterium; and at least one of R1-R27 is deuterium.
Drugs covered by this patent
Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.
Track this patent
Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.